JCO Editorial: (pdf) + link to original article abstract - Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials (breast, cervical, endometrial, ovarian) : The Case of PI3K Inhibitors Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, January 28, 2012

JCO Editorial: (pdf) + link to original article abstract - Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials (breast, cervical, endometrial, ovarian) : The Case of PI3K Inhibitors



Editorial:

"On the basis of these considerations, with mTOR and pan-PI3K
inhibitors we might need to cast a wider net and study patients with
mutations of the target gene(s) within the pathway, as well as those
without such mutations, until a stronger predictive relationship
emerges. Regardless, the availability of tumor samples should be mandatory,
and, in those cases with demonstrated clinical responses, we
should be ready to embark in deep sequencing analysis in order to
identify potential mutations indicative of sensitivity to the agents
under study."

abstract: original article:

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations



0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.